Sale!

SLC34A1 Gene Nephrolithiasisosteoporosis Hypophosphatemic Type 1 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The SLC34A1 gene plays a critical role in phosphate homeostasis by encoding a sodium-phosphate co-transporter that is primarily expressed in the kidney. Mutations in this gene can lead to a rare condition known as nephrolithiasis/osteoporosis, hypophosphatemic, type 1 (NPHLOP1). This disorder is characterized by reduced phosphate reabsorption in the kidneys, leading to low levels of phosphate in the blood (hypophosphatemia), which can result in the development of kidney stones (nephrolithiasis) and weakened bones prone to fractures (osteoporosis).

To diagnose this condition, genetic testing of the SLC34A1 gene is essential. DNA Labs UAE offers a comprehensive genetic test for the SLC34A1 gene to identify mutations associated with nephrolithiasis/osteoporosis, hypophosphatemic, type 1. The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any genetic variations that could lead to the disorder.

This test is particularly important for individuals with a family history of the condition or those exhibiting symptoms, as early detection can facilitate better management and treatment strategies to mitigate the impact of the disease. DNA Labs UAE employs state-of-the-art technology and follows rigorous protocols to ensure the accuracy and reliability of the test results.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

SLC34A1 Gene Nephrolithiasisosteoporosis hypophosphatemic type 1 Genetic Test

Genetic testing plays a crucial role in diagnosing and understanding various genetic disorders. One such test is the SLC34A1 Gene Nephrolithiasisosteoporosis hypophosphatemic type 1 Genetic Test, offered by DNA Labs UAE.

Test Details

The SLC34A1 gene is responsible for encoding a protein called sodium-phosphate cotransporter 2a (NPT2a), which plays a crucial role in the reabsorption of phosphate in the kidneys. Mutations in this gene can lead to a condition called hypophosphatemic nephrolithiasis/osteoporosis, type 1. To diagnose this condition, DNA Labs UAE offers the SLC34A1 Gene Nephrolithiasisosteoporosis hypophosphatemic type 1 Genetic Test.

The test utilizes NGS (Next-Generation Sequencing) technology, which allows for the simultaneous analysis of multiple genes. By screening for mutations in the SLC34A1 gene, the test can provide valuable information for healthcare providers to better understand the underlying cause of nephrolithiasis/osteoporosis, type 1.

Test Components and Price

The SLC34A1 Gene Nephrolithiasisosteoporosis hypophosphatemic type 1 Genetic Test is priced at 4400.0 AED. The sample condition required for the test can be either blood, extracted DNA, or one drop of blood on an FTA card.

Report Delivery and Method

Once the sample is received, the report delivery takes approximately 3 to 4 weeks. The test utilizes NGS technology for accurate and comprehensive analysis.

Test Type and Doctor

The SLC34A1 Gene Nephrolithiasisosteoporosis hypophosphatemic type 1 Genetic Test falls under the category of Hepatology, Nephrology, and Endocrinology Disorders. It is recommended to consult a General Physician for this test.

Test Department and Pre Test Information

The test is conducted in the Genetics department of DNA Labs UAE. It is essential to provide the clinical history of the patient who is going for the test, especially if they have a family history of SLC34A1 Gene Nephrolithiasis/osteoporosis, hypophosphatemic, type 1. A Genetic Counselling session may be conducted to draw a pedigree chart of family members affected by this genetic condition.

Conclusion

The SLC34A1 Gene Nephrolithiasisosteoporosis hypophosphatemic type 1 Genetic Test offered by DNA Labs UAE is a valuable tool for diagnosing and understanding the underlying cause of nephrolithiasis/osteoporosis, type 1. By identifying mutations in the SLC34A1 gene, healthcare providers can make informed treatment decisions and provide appropriate genetic counseling to affected individuals and their families.

Test Name SLC34A1 Gene Nephrolithiasisosteoporosis hypophosphatemic type 1 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Hepatology Nephrology Endocrinology Disorders
Doctor General Physician
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for SLC34A1 Gene Nephrolithiasis/osteoporosis, hypophosphatemic, type 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SLC34A1 Gene Nephrolithiasis/osteoporosis, hypophosphatemic, type 1 NGS Genetic DNA Test gene SLC34A1
Test Details

The SLC34A1 gene is responsible for encoding a protein called sodium-phosphate cotransporter 2a (NPT2a). This protein plays a crucial role in the reabsorption of phosphate in the kidneys.

Nephrolithiasis, also known as kidney stones, and osteoporosis are two conditions that can be associated with mutations in the SLC34A1 gene. Specifically, mutations in this gene can lead to a condition called hypophosphatemic nephrolithiasis/osteoporosis, type 1.

NGS (Next-Generation Sequencing) genetic testing is a method used to analyze multiple genes simultaneously and identify potential mutations or variants that may be contributing to a specific condition. In the context of nephrolithiasis/osteoporosis, type 1, NGS genetic testing can be used to screen for mutations in the SLC34A1 gene to help diagnose the condition.

By identifying mutations in the SLC34A1 gene, NGS genetic testing can provide valuable information for healthcare providers to better understand the underlying cause of nephrolithiasis/osteoporosis, type 1. This information can then be used to guide treatment decisions and provide appropriate genetic counseling to affected individuals and their families.